{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T15:17:41Z","timestamp":1726759061706},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.033","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:04:58Z","timestamp":1254218698000},"page":"S340-S345","source":"Crossref","is-referenced-by-count":11,"special_numbering":"S3","title":["JAK2 Inhibitors: A Reality? A Hope?"],"prefix":"10.3816","volume":"9","author":[{"given":"Effrosyni","family":"Apostolidou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagop M.","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.033_bib1","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.4065\/73.12.1177","article-title":"The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview","volume":"73","author":"Tefferi","year":"1998","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLM.2009.s.033_bib2","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1182\/blood.V95.7.2226","article-title":"Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients","volume":"95","author":"Tefferi","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/00062752-199809000-00004","article-title":"Bleeding and thrombosis in myeloproliferative disorders","volume":"5","author":"Landolfi","year":"1998","journal-title":"Curr Opin Hematol"},{"key":"10.3816\/CLM.2009.s.033_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1034\/j.1600-0609.2001.00342.x","article-title":"Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia","volume":"66","author":"Tefferi","year":"2001","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.s.033_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1055\/s-0038-1650579","article-title":"Erythromelalgia in essential thrombocythemia is characterized by platelet activation and endothelial cell damage but not by thrombin generation","volume":"76","author":"van Genderen","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.3816\/CLM.2009.s.033_bib6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1378\/chest.120.3.801","article-title":"Unexplained pulmonary hypertension in chronic myeloproliferative disorders","volume":"120","author":"Dingli","year":"2001","journal-title":"Chest"},{"key":"10.3816\/CLM.2009.s.033_bib7","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1046\/j.1365-2141.2001.02796.x","article-title":"Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia","volume":"113","author":"Tefferi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.033_bib8","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1182\/blood.V88.3.1013.1013","article-title":"Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system","volume":"88","author":"Dupriez","year":"1996","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib9","doi-asserted-by":"crossref","first-page":"3374","DOI":"10.1182\/blood.V96.10.3374","article-title":"Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia","volume":"96","author":"Mesa","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib10","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib11","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1182\/blood-2003-06-1856","article-title":"Allogeneic hematopoietic stem cell transplantation for myelofibrosis","volume":"102","author":"Deeg","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib12","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2004.05229.x","article-title":"Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature","volume":"127","author":"Cervantes","year":"2004","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.033_bib13","first-page":"595","article-title":"Danazol treatment of idiopathic myelofibrosis with severe anemia","volume":"85","author":"Cervantes","year":"2000","journal-title":"Haematologica"},{"key":"10.3816\/CLM.2009.s.033_bib14","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1600-0609.1990.tb00344.x","article-title":"Reversal of myelofibrosis by hydroxyurea","volume":"44","author":"Lofvenberg","year":"1990","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.s.033_bib15","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1097\/00000441-198805000-00011","article-title":"Remission of chronic idiopathic myelofibrosis to busulfan treatment","volume":"295","author":"Chang","year":"1988","journal-title":"Am J Med Sci"},{"key":"10.3816\/CLM.2009.s.033_bib16","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.0007-1048.2001.03331.x","article-title":"Melphalan treatment in patients with myelofibrosis with myeloid metaplasia","volume":"116","author":"Petti","year":"2002","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.033_bib17","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1600-0609.2004.00370.x","article-title":"Long-term analysis of the palliative benefit of 2-chlorodeoxyadenosine for myelofibrosis with myeloid metaplasia","volume":"74","author":"Faoro","year":"2005","journal-title":"Eur J Haematol"},{"key":"10.3816\/CLM.2009.s.033_bib18","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJM197406132902419","article-title":"Letter: Bone-marrow responses in polycythemia vera","volume":"290","author":"Prchal","year":"1974","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.033_bib19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1182\/blood.V80.4.891.891","article-title":"Polycythemia vera. II. Hypersensitivity of bone marrow erythroid, granulocyte-macrophage, and megakaryocyte progenitor cells to interleukin-3 and granulocyte-macrophage colony-stimulating factor","volume":"80","author":"Dai","year":"1992","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib20","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2141.1994.tb08300.x","article-title":"Spontaneous megakaryocyte colony formation in myeloproliferative disorders is not neutralizable by antibodies against IL3, IL6 and GM-CSF","volume":"87","author":"Li","year":"1994","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.033_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1365-2141.1993.tb04688.x","article-title":"Circulating megakaryocyte progenitors in myeloproliferative disorders are hypersensitive to interleukin-3","volume":"83","author":"Kobayashi","year":"1993","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.033_bib22","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood.V96.10.3310","article-title":"Hypersensitivity of circulating progenitor cells to megakaryocyte growth and development factor (PEG-rHu MGDF) in essential thrombocythemia","volume":"96","author":"Axelrad","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib23","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0268-960X(97)90021-7","article-title":"Pathogenesis of polycythaemia vera","volume":"11","author":"Hinshelwood","year":"1997","journal-title":"Blood Rev"},{"key":"10.3816\/CLM.2009.s.033_bib24","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","article-title":"The molecular biology of chronic myeloid leukemia","volume":"96","author":"Deininger","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0268-960X(03)00024-9","article-title":"Receptor tyrosine kinases in normal and malignant haematopoiesis","volume":"17","author":"Reilly","year":"2003","journal-title":"Blood Rev"},{"key":"10.3816\/CLM.2009.s.033_bib26","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2003-11-3896","article-title":"After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies","volume":"105","author":"Wadleigh","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1146\/annurev.iy.13.040195.002101","article-title":"Signaling through the hematopoietic cytokine receptors","volume":"13","author":"Ihle","year":"1995","journal-title":"Annu Rev Immunol"},{"key":"10.3816\/CLM.2009.s.033_bib28","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.033_bib29","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.3816\/CLM.2009.s.033_bib30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2009.s.033_bib31","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2009.s.033_bib32","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib33","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib34","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1371\/journal.pone.0000018","article-title":"Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F","volume":"1","author":"Zaleskas","year":"2006","journal-title":"PLoS ONE"},{"key":"10.3816\/CLM.2009.s.033_bib35","doi-asserted-by":"crossref","first-page":"11156","DOI":"10.1158\/0008-5472.CAN-06-2210","article-title":"Characterization of murine JAK2V617Fpositive myeloproliferative disease","volume":"66","author":"Bumm","year":"2006","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.033_bib36","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"10.3816\/CLM.2009.s.033_bib37","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib38","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.033_bib39","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0960-894X(02)00106-3","article-title":"Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor","volume":"12","author":"Thompson","year":"2002","journal-title":"Bioorg Med Chem Lett"},{"key":"10.3816\/CLM.2009.s.033_bib40","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1182\/blood-2005-06-2413","article-title":"The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor","volume":"107","author":"Lucet","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib41","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/sj.leu.2404750","article-title":"TG10 1209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L\/K mutations","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.033_bib42","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1182\/blood-2005-02-0707","article-title":"Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog","volume":"106","author":"Boggon","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib43","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.leu.2404948","article-title":"JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials","volume":"22","author":"Pardanani","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.033_bib44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1182\/blood-2006-05-025049","article-title":"MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T3 15I BCRABL mutation","volume":"109","author":"Giles","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib45","doi-asserted-by":"crossref","first-page":"5663","DOI":"10.1182\/blood-2007-04-083402","article-title":"Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2\/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders","volume":"111","author":"Hexner","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib46","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1074\/jbc.C600277200","article-title":"Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth","volume":"282","author":"Li","year":"2007","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2009.s.033_bib47","doi-asserted-by":"crossref","first-page":"1035a","DOI":"10.1182\/blood.V110.11.3537.3537","article-title":"AT9283, a potent inhibitor of JAK2, is active in JAK2 V617F myeloproliferative disease models","volume":"110","author":"Squires","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib48","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1365-2141.2006.06291.x","article-title":"Go6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells","volume":"135","author":"Grandage","year":"2006","journal-title":"Br J Haematol"},{"key":"10.3816\/CLM.2009.s.033_bib49","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.leukres.2006.12.025","article-title":"Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis","volume":"31","author":"Elliott","year":"2007","journal-title":"Leuk Res"},{"key":"10.3816\/CLM.2009.s.033_bib50","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1158\/1078-0432.CCR-06-2116","article-title":"Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer","volume":"13","author":"Fridman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.033_bib51","unstructured":"Incyte C. Investigator's brochure. INCB01 8424. Phosphate capsules\/tablets."},{"key":"10.3816\/CLM.2009.s.033_bib52","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2006-03-009746","article-title":"International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)","volume":"108","author":"Tefferi","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib53","doi-asserted-by":"crossref","first-page":"171a","DOI":"10.1182\/blood.V110.11.558.558","article-title":"INCB01 8424, an oral, selective JAK2 inhibitor, shows significant clinical activity in a phase I\/II study in patients with primary myelofibrosis (PMF) and post polycythemia vera\/essential thrombocythemia myelofibrosis (Post-PV\/ET MF)","volume":"110","author":"Verstovsek","year":"2007","journal-title":"Blood"},{"issue":"suppl","key":"10.3816\/CLM.2009.s.033_bib54","first-page":"373s","article-title":"A phase I\/II study of INCB018424, an oral, selective JAK inhibitor, in patients with primary myelofibrosis (PMF) and post polycythemia vera\/essential thrombocythemia myelofibrosis (Post-PV\/ET MF)","volume":"26","author":"Verstovsek","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.033_bib55","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1762.1762","article-title":"The JAK inhibitor, INCB01 8424, demonstrates durable and marked clinical responses in primary myelofibrosis (PMF) and post-polycythemia\/essential thrombocythemia myelofibrosis (Post PV\/ETMF)","volume":"112","author":"Verstovsek","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib56","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.1754.1754","article-title":"Assessment and monitoring of constitutional symptoms in patients with myelofibrosis: a proposed new instrument the myelofibrosis symptom assessment form (MFSAF)","volume":"112","author":"Mesa","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib57","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2804.2804","article-title":"The clinical phenotype of myelofibrosis encompasses a chronic inflammatory state that is favorably altered by INCB01 8424, a selective inhibitor of JAK1\/2","volume":"112","author":"Tefferi","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib58","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.2802.2802","article-title":"Characterization of JAK2 V617F allele burden in advanced myelofibrosis (MF) patients: no change in V617F:WT JAK2 ratio in patients with high allele burdens despite profound clinical improvement following treatment with the JAK inhibitor, INCB01 8424","volume":"112","author":"Verstovsek","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib59","first-page":"170a","article-title":"A phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis and post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"110","author":"Verstovsek","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib60","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.98.98","article-title":"A Phase I study of XL019, a selective JAK2 inhibitor, in patients with primary myelofibrosis, post-polycythemia vera, or postessential thrombocythemia myelofibrosis","volume":"112","author":"Shah","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib61","doi-asserted-by":"crossref","first-page":"1026a","DOI":"10.1182\/blood.V108.11.3594.3594","article-title":"CEP-701 is a JAK2 inhibitor which attenuates JAK2\/STAT5 signaling pathway and the proliferation of primary cells from patients with myeloproliferative disorders","volume":"108","author":"Dobrzanski","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib62","first-page":"1037a","article-title":"Phase II study of CEP701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"110","author":"Verstovsek","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib63","doi-asserted-by":"crossref","unstructured":"Santos F, Kantarjian HK, Jain NJ, et al. Phase II study of CEP-701, an orally available JAK2 inhibitor, in patients with primary myelofibrosis and post polycythemia vera\/essential thrombocythemia myelofibrosis. Presented at: the European Hematology Association meeting; Berlin, Germany; June 2009.","DOI":"10.1182\/blood-2009-10-246363"},{"key":"10.3816\/CLM.2009.s.033_bib64","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a Selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"10.3816\/CLM.2009.s.033_bib65","unstructured":"Pardanani D, Gotlib J, Jamieson C, et al. TG101348, A JAK2-selective inhibitor, is well tolerated in patients with myelofibrosis and shows substantial therapeutic activity accompanied by a reduction in JAK2V617F allele burden. Presented at: the European Hematology Association meeting; Berlin, Germany; June 2009."},{"key":"10.3816\/CLM.2009.s.033_bib66","article-title":"Selective targeting of the JAK2V617F mutation in polycythemia vera and essential thrombocythemia by ITF2357, a novel histone deacetylase inhibitor","volume":"110","author":"Guerini","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib67","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.100.100","article-title":"A Phase 2A study of the histone deacetylase inhibitor ITF2357 in patients with Jak2V617F positive chronic myeloproliferative neoplasms","volume":"112","author":"Rambaldi","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.033_bib68","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703614?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703614?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T15:47:22Z","timestamp":1590162442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":68,"alternative-id":["S1557919011703614"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.033","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}